Tafero (Tenofovir Alafenamide)

Tenofovir Alafenamide
Contact us for more information
Wishlist Compare
Hetero Drugs Ltd

Tafero (Tenofovir Alafenamide)

ManufacturerHetero Drugs LtdBrand nameTaferoInternational trade nameVemlidyActive substanceTenofovir AlafenamideStrength25mgCategoryHEPATITIS B, HIV

Description of Tafero 25mg (Tenofovir Alafenamide 25mg)

Tafero 25mg (Tenofovir Alafenamide 25mg) is an anti-hepaciviral & anti-retroviral medicine. In HIV infected patients, Tafero 25mg (Tenofovir Alafenamide 25mg) is not used alone and it may combine with some other anti-retroviral drugs like Emtricitabine, cobicistat, or darunavir. At first, Tafero 25mg (Tenofovir Alafenamide 25mg) is belongs to anti-retroviral (nucleoside reverse transcriptase inhibitor), now Tafero 25mg (Tenofovir Alafenamide 25mg) has anti-hepaciviral property which is used against hepatitis B viral infection

Medical use /Indication of Tafero 25mg (Tenofovir Alafenamide 25mg)

Prior usage of Tafero 25mg (Tenofovir Alafenamide 25mg) tablet, used in HIV-1 infection Tafero 25mg (Tenofovir Alafenamide 25mg) tablet is also indicated for the treatment of hepatitis B viral infection, by reducing the advancement of virus Tafero 25mg (Tenofovir Alafenamide 25mg) used in chronic hepatitis B infection, is non-curable but it can able to prevent the viral transmission


Anti-retroviral drug
Anti-hepaciviral drug

Works as of Tafero 25mg (Tenofovir Alafenamide 25mg)

Tafero 25mg (Tenofovir Alafenamide 25mg)-Tenofovir Alafenamide (TAF) TAF is a prodrug of tenofovir (parent drug) At first, TAF is penetrating into hepatic cells because it has lipophilic cell permeable capacity. After enters into the cells, TAF undergoes hydrolysis by using carboxylesterase-1 and to formed as tenofovir. Tenofovir involved in intracellular metabolism, which is phosphorylated into tenofovir triphosphate. Tenofovir triphosphate is considered as an active metabolite which has anti-viral property and integrated into viral DNA by hepatitis B reverse transcriptase enzyme and leads to inhibits viral production thus results as termination of viral chain.

How the body works for Tafero 25mg (Tenofovir Alafenamide 25mg) 

After an oral administration, absorption of Tafero 25mg (Tenofovir Alafenamide 25mg) tablet occurs rapidly. The peak plasma time occurs within 0.48 hours The effect of food while taking Tafero 25mg (Tenofovir Alafenamide 25mg) tablet is includes as; With high fat meal, the effect of Tenofovir Alafenamide is 1.65 Tafero 25mg (Tenofovir Alafenamide 25mg) is highly bound to human plasma protein nearly 80% The blood plasma ration is 1.0 Metabolism of Tenofovir Alafenamide is occurs with the aid of cathepsin A, carboxylesterase-1 The half life period of Tenofovir Alafenamide is 0.51 hour Excretion occurs through urine <1%; feces 31.7%

Side effects of Tafero 25mg (Tenofovir Alafenamide 25mg)

Important adverse effects;'

Lactic acidosis or severe hepatomegaly with steatosis
Reactivation of hepatitis B viral infection in worsening condition after the therapy
Renal damage occurs
Some of undesirable effects;
Back pain
Abdominal pain
Reduction in bone mineral density
Creatine kinase elevation
Amylase lipase elevated.

Precaution of Tafero 25mg (Tenofovir Alafenamide 25mg)

  1. After cessation of anti-hepatitis B therapy by using with Tafero 25mg (Tenofovir Alafenamide 25mg) tablet, concluded in serious intense aggravation of hepatitis B infection. To avoid this adverse condition in the patients, liver function should be observed frequently.
  2. Exposure of reinforcement of HIV-1 antagonism in HBV/HIV-1 co infected patients In HIV infected patients, combinational therapy is suggested for avoiding this condition in co-infected patients. Check the HIV antibody in all HBV infected patients before starting the therapy.
  3. New commencement and worsening of renal damage Patient with low renal function capability, stop the Tafero 25mg (Tenofovir Alafenamide 25mg)tablet therapy immediately and monitored the serum phosphorus, serum creatinine, urine protein, urine glucose and creatinine clearance frequently
    4. Lactic acidosis or serious hepatomegaly with steatosis If this condition occurred in the patients, immediately discontinue the therapy and provide safety measures

Drug interaction of Tafero 25mg (Tenofovir Alafenamide 25mg)

Tafero 25mg (Tenofovir Alafenamide 25mg) combined with P-gp or BCRP strong inhibitors, results as alteration of absorption of Tenofovir Alafenamide P-gp or BCRP inducers, combined with Tafero 25mg (Tenofovir Alafenamide 25mg) tablets leads to cause loss of therapeutic effect of Tafero 25mg (Tenofovir Alafenamide 25mg). Tafero 25mg (Tenofovir Alafenamide 25mg) with P-gp or BCRP moderate inhibitors results as absorption elevation thus causes plasma concentration of Tenofovir Alafenamide. Tafero 25mg (Tenofovir Alafenamide 25mg) tablets combined with anti-convulsants (phenytoin, carbamazepine, or Phenobarbital), anti-mycobacterials (rifampin, rifapentine, or rifabutin) or herbal products (st Johns wort) causes depletion in effect of concentration of Tafero 25mg (Tenofovir Alafenamide 25mg).

Over dosage of Tafero 25mg (Tenofovir Alafenamide 25mg)

In over dosage condition, two steps follows :
1. Examine the deposition of toxicity and symptoms occurred due to over dosage
2. Hemodialysis, a method involved in eradicating the over dosage of Tafero 25mg (Tenofovir Alafenamide 25mg) with separation coefficient of 54%

Pregnancy & Lactation of Tafero 25mg (Tenofovir Alafenamide 25mg)

Tafero 25mg (Tenofovir Alafenamide 25mg) is rational use, in some patients placental transformation happens

In breast feeding and lactation condition, Tafero 25mg (Tenofovir Alafenamide 25mg) is used only under the guidance of medical practitioner.

Dosage of Tafero 25mg (Tenofovir Alafenamide 25mg)

The usual dosage of Tafero 25mg (Tenofovir Alafenamide 25mg) tablet is, one tablet containing 25mg of Tenofovir Alafenamide should be taken as a single dose Tafero 25mg (Tenofovir Alafenamide 25mg) tablet should be administered with food In creatinine clearance range <15ml/min, Tafero 25mg (Tenofovir Alafenamide 25mg) is not recommended In decompensated cirrhosis: Tafero 25mg (Tenofovir Alafenamide 25mg) should not be recommended Before initiating the therapy: Patients should examine HIV-1 infection for recommending combination of other anti-retroviral drugs in HIV-1 positive patients.

Storage of Tafero 25mg (Tenofovir Alafenamide 25mg)

Tafero 25mg (Tenofovir Alafenamide 25mg) tablets container is stored under room temperature below 30 ℃. Tafero 25mg (Tenofovir Alafenamide 25mg) container should be kept in dry and cool place and should be free from heat, moisture Protect from light

Missed dose of Tafero 25mg (Tenofovir Alafenamide 25mg)

Once missed dose occurred, patient must consult with medical practitioner and follow the instruction. On another way, missed dose should be skipped and proceed from regular dosing schedule.

Brand name:
International trade name:
Active substance:
Tenofovir Alafenamide
Hetero Healthcare Ltd
30 Tablet
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India